JR-213

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: JR-213
• 英文别名: 1-[Naphthalen-2-yl-methylideneamino]guanidine Hydrochloride；2-(naphthalen-2-ylmethylideneamino)guanidine;hydrochloride
• 化学式: C₁₂H₁₂N₄*ClH
• 分子量: 248.715
• InChiKey: KUPZMLHGEHATMY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.87
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  76.8
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-(1-naphthalenylmethylene)hydrazinecarboximidamide 在 盐酸 作用下， 以 乙醚 、 乙酸乙酯 为溶剂， 以216 mg的产率得到JR-213
  参考文献：
  名称：

  Synthesis and biological evaluation of guanylhydrazone coactivator binding inhibitors for the estrogen receptor

  摘要：

  Most patients with hormone-responsive breast cancer eventually develop resistance to traditional antiestrogens such as tamoxifen, and this has become a major obstacle in their treatment. We prepared and characterized the activity of a series of 16 guanylhydrazone small molecules that are designed to block estrogen receptor (ER) activity through a non-traditional mechanism, by directly interfering with coactivator binding to agonist-liganded ER. The inhibitory activity of these compounds was determined in cell-based transcription assays using ER-responsive reporter gene and mammalian two-hybrid assays. Several of the compounds gave IC50 values in the low micromolar range. Two secondary assays were used to confirm that these compounds were acting through the proposed non-traditional mode of estrogen inhibitory action and not as conventional antagonists at the ligand binding site. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2008.10.007

文献信息

• Aminoguanidine Hydrazone Derivatives as Nonpeptide NPFF1 Receptor Antagonists Reverse Opioid Induced Hyperalgesia
  作者：Hassan Hammoud、Khadija Elhabazi、Raphäelle Quillet、Isabelle Bertin、Valérie Utard、Emilie Laboureyras、Jean-Jacques Bourguignon、Frédéric Bihel、Guy Simonnet、Frédéric Simonin、Martine Schmitt

  DOI：10.1021/acschemneuro.8b00099

  日期：2018.11.21

  this work, we sought to identify novel NPFF receptors ligands by focusing our interest in a series of heterocycles as rigidified nonpeptide NPFF receptor ligands, starting from already described aminoguanidine hydrazones (AGHs). Binding experiments and functional assays highlighted AGH 1n and its rigidified analogue 2-amino-dihydropyrimidine 22e for in vivo experiments. As shown earlier with the prototypical

  先前已显示神经肽FF受体（NPFF1R和NPFF2R）及其内源性配体神经肽FF具有抗阿片类药物的特性，并且在鸦片类药物长期服用相关的不良反应中起关键作用，包括阿片类药物引起的痛觉过敏和镇痛耐受性的发展。在这项工作中，我们试图通过将我们的注意力集中在一系列杂环上来鉴定新的NPFF受体配体，这些杂环作为刚性化的非肽NPFF受体配体，从已经描述的氨基胍（AGH）开始。结合实验和功能测定突出了用于体内实验的AGH 1n及其刚性化类似物2-氨基-二氢嘧啶22e。如先前使用原型二肽拮抗剂RF9所示，1n和22e均显着降低了芬太尼诱导的鼠持久性痛觉过敏。总而言之，这些数据表明，AGH硬化对两种NPFF受体均保持纳摩尔亲和力，同时改善了对NPFF1R的拮抗特性。
• Treating neuropathic pain with neuropeptide FF receptor 2 agonists
  申请人：Scully L. Audra

  公开号：US20050136444A1

  公开（公告）日：2005-06-23

  The invention described below relates to the discovery of the neuropeptide FF receptor subtype that mediates acute nociception and chronic neuropathic pain, compounds that selectively interact with this receptor subtype and methods for treating acute pain and chronic neuropathic pain.

  以下所描述的发明涉及到发现了介导急性痛觉和慢性神经病理性疼痛的神经肽FF受体亚型、与该受体亚型有选择性相互作用的化合物以及治疗急性疼痛和慢性神经病理性疼痛的方法。
• Improving the inhibitory activity of arylidenaminoguanidine compounds at the N-methyl-d-aspartate receptor complex from a recursive computational-experimental structure–activity relationship study
  作者：Joshua R. Ring、Fang Zheng、Aaron J. Haubner、John M. Littleton、Peter A. Crooks

  DOI：10.1016/j.bmc.2013.01.051

  日期：2013.4

  Using a combination of both the partial least squares (PLS) and back-propagation artificial neural network (ANN) pattern recognition methods, several models have been developed to predict the activity of a series of arylidenaminoguanidine analogs as inhibitory modulators of the N-methyl-D-aspartate receptor complex. This was done by correlating structural and physicochemical descriptors obtained from computation software with the experimentally observed [H-3]MK-801 displacement ability of a small library of synthesized and in vitro screened arylidenaminoguanidines. Results for the generated PLS model were r(2) = 0.814, rmsd = 0.208, r(CV)(2) = 0.714, loormsd = 0.261. The ANN model was created utilizing the eleven descriptors from the PLS model for comparison. The quality of the ANN model (r(2)=0.828, rmsd = 0.200, r(CV)(2) = 0.721, loormsd = 0.257) is similar to the PLS model, and indicates that the feature between the inputs and the output is majorly linear. These computational models were able to predict inhibition of the NMDA receptor complex by this series of compounds in silico, affording a predictive structure-based 'pre-screening' paradigm for the arylideneaminoguanidine analogs. (C) 2013 Elsevier Ltd. All rights reserved.
• Synthesis and biological evaluation of guanylhydrazone coactivator binding inhibitors for the estrogen receptor
  作者：Andrew L. LaFrate、Jillian R. Gunther、Kathryn E. Carlson、John A. Katzenellenbogen

  DOI：10.1016/j.bmc.2008.10.007

  日期：2008.12

  Most patients with hormone-responsive breast cancer eventually develop resistance to traditional antiestrogens such as tamoxifen, and this has become a major obstacle in their treatment. We prepared and characterized the activity of a series of 16 guanylhydrazone small molecules that are designed to block estrogen receptor (ER) activity through a non-traditional mechanism, by directly interfering with coactivator binding to agonist-liganded ER. The inhibitory activity of these compounds was determined in cell-based transcription assays using ER-responsive reporter gene and mammalian two-hybrid assays. Several of the compounds gave IC50 values in the low micromolar range. Two secondary assays were used to confirm that these compounds were acting through the proposed non-traditional mode of estrogen inhibitory action and not as conventional antagonists at the ligand binding site. (c) 2008 Elsevier Ltd. All rights reserved.